The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

With a market cap of $10.7 billion, Catalent, Inc. (CTLT) is a leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

BRUSSELS/LONDON, Nov 22 (Reuters) - Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent (CTLT.N), opens new ...

CIBC Asset Management Inc grew its holdings in shares of Catalent, Inc. (NYSE:CTLT – Free Report) by 7.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities ...

Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock from a Hold ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent, people familiar with the ...